Can Adding Radium-223 to RT Boost Prostate Cancer Outcomes?
Unpacking the Latest Findings in Prostate Cancer Treatment Recent studies, such as the multicenter phase 2 RAVENS trial, shed light on evolving strategies against metastatic prostate cancer. The trial evaluated the efficacy of combining radium-223 dichloride (Ra223) with metastasis-directed stereotactic ablative radiotherapy (SABR) in treating bone-only oligometastatic castration-sensitive prostate cancer. Though the combination showed no … Read more